This observational study was conducted to assess the efficacy and safety of generic imatinib in 91 patients with chronic myeloid leukemia (either treated first-line or switched from patented to generic imatinib). Efficacy and safety of generic imatinib was comparable with patented imatinib. These results support the use of generic imatinib to reduce health care expenditure per patient and increase patient access. Introduction: Generic imatinib therapy is being globally considered owing to cost considerations. However, evidence of its efficacy and safety in Middle Eastern clinical settings is scarce. Patients and Methods: The efficacy and safety of generic imatinib (Cemivil) were assessed among Jordanian patients diagnosed with chronic myeloid leukemia using an observational, multicenter, prospective study design. Responses were defined using European LeukemiaNet 2009 guidelines and assessed by complete blood counts, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Results: All patients (N ¼ 91) were adults with chronic myeloid leukemia treated with generic imatinib 400 mg/day. Thirty-three patients received generic imatinib as first-line therapy, and 58 switched from patented imatinib to generic imatinib after a median of 4.5 years (range, 0.5-13.6 years) of imatinib therapy. The majority (85%; n ¼ 28) of the first-line patients achieved complete hematologic response within 3 months of starting generic imatinib therapy (100% after 6 months [n ¼ 33]). The 12-month major molecular response rate in the intentionto-treat population was 45%. The 12-month major molecular response rate was 88% for patients who switched therapy. The 12-month progression-free and overall survival rates were 92% and 100%, respectively. Most (85%; n ¼ 144) adverse events were mild. Frequencies of drug-related adverse events were similar to patented imatinib. Conclusion: This study suggests that the efficacy and safety of generic imatinib in this Middle Eastern population in routine clinical practice are comparable to patented imatinib, and to that of the global population.
Introduction
The outcome of patients with chronic myeloid leukemia (CML) has been revolutionized by imatinib, a selective inhibitor of BCR-ABL1 tyrosine kinase. The 2009 and 2013 European LeukemiaNet (ELN) guidelines advise the use of imatinib 400 mg daily as first-line therapy for patients with CML in chronic phase (CP). 1, 2 The high economic burden of patented medications such as imatinib has been of concern even in Western nations. 3 Approximately 85% of patients are diagnosed with CML in CP. In the pivotal randomized International Randomized Study of Interferon and STI571 (IRIS) clinical trial, patients initially treated with imatinib had a significantly lower risk of disease progression to accelerated or blast phase, with an overall survival (OS) rate of 90% after 5 years. 4, 5 Although second-generation tyrosine kinase inhibitors (TKIs) (eg, dasatinib or nilotinib) produced more rapid molecular responses than imatinib, 5-year OS was similar to that of imatinib. 2, [5] [6] [7] [8] Thus, generic imatinib is more cost-effective 1 than other TKIs, 9 leading to consensus recommendations that most patients should receive imatinib as first-line therapy. 10, 11 Today, generic imatinib (Cemivil, Hikma Pharmaceuticals) is available in Jordan, Egypt, Tunisia, Morocco, and Libya. It was launched after bioequivalence with patented imatinib was demonstrated by investigating pharmacokinetic parameters in a randomized, laboratory-blinded, crossover study. 12 Still, evidence of its safety and efficacy in routine clinical setting is scarce. The current observational study was designed to assess the safety and efficacy of the standard 400 mg/day dose of generic imatinib for an observation period of 12 months in routine clinical practice in Jordan.
Materials and Methods

Study Design and Participants
In this multicenter, observational, open-label study, we identified 91 patients who were treated with generic imatinib in 3 clinical centers in Amman, Jordan. Adults (age 18 years) with Philadelphia chromosome-positive (Phþ) CML in CP, who were either treated with first-line generic imatinib or who were switched from patented to generic imatinib, were eligible for the current study. Data were collected prospectively and retrospectively, depending on study initiation date (August 15, 2012). The last patient visit was in February 2015.
Based on the availability of generic imatinib in Jordan (launched on January 1, 2011), 2 groups of patients were identified: (1) patients diagnosed with CML after January 1, 2011, and who started first-line treatment with generic imatinib (ie, "first-line patients"); and (2) patients diagnosed with CML before January 1, 2011 who were previously treated with patented imatinib and then switched to generic imatinib when it became available on January 1, 2011 (ie, "switched patients").
The study was performed in accordance with local regulations and the Declaration of Helsinki. The protocol was reviewed and approved by the ethic committees of each participating center, and written informed consent was obtained from all patients before entry. This study is registered in ClinicalTrials.gov (reference number NCT02977312).
Procedures, Objectives, and Endpoints
Patients were treated with generic imatinib (400 mg/tablet) for a scheduled observation period of 12 months. The proportions of first-line and switched patients who achieved optimal response at 12 months of treatment with generic imatinib, as defined in the 2009 ELN guidelines for complete hematologic response (CHR), complete cytogenetic response (CCyR), and major molecular response (MMR), were assessed. 1 The procedures used to assess efficacy, which are routinely used in clinical practice in Jordan and are compatible with the 2009 ELN guidelines, 1 The safety/tolerability of generic imatinib and compliance with treatment were also assessed at each visit.
All data were analyzed in a descriptive, exploratory manner. Continuous variables were summarized using descriptive statistics (mean, standard deviation [SD], median, and range). Qualitative variables were summarized using counts, percentages, and 95% confidence intervals (CIs) when applicable. Missing data were not replaced. All statistical analyses were performed using SAS for Windows (Version 9.3). All patients who entered the study and received study drug were included in the safety analysis.
Responses are reported based on the 2009 ELN definitions owing to their use in the study protocol, which was written before publication of the 2013 ELN definitions 2 and 2016 US National
Comprehensive Cancer Network (NCCN) recommendations. 13 
Results
Patient Characteristics
Of the 91 patients who started the study, 86 (94.5%) completed the 12-month observation period ( Figure 1 ). The median age of the study cohort was 48.0 years (range, 18.0-86.0 years). Thirty-three (36%) patients received imatinib as first-line treatment, whereas 58 (64%) patients switched from patented imatinib to generic imatinib and had been diagnosed with CML for a median duration of 4.5 years (range, 0.5-13.6 years) ( Figure 1 , Table 1 ).
The majority of the 91 (89%) patients received 400 mg/day generic imatinib as the initial dose (100% first-line patients, 83% switched patients) ( Table 1 ). Most patients (80%) maintained the same dose throughout the treatment period; 18 patients had their dose changed as per the physician's medical judgment (increased in 11 patients, decreased in 6 patients [n ¼ 1 owing to hematologic adverse event (AE), n ¼ 1 owing to nonhematologic AE, n ¼ 4 for Generic Imatinib Therapy Among Jordanians reasons not disclosed], and 1 patient had a dose change in an undisclosed direction). Eight (9%) patients did not have continuous therapy during the 12-month observation period; they temporarily withdrew because of an AE and resumed with the same dose. Treatment compliance was assessed by the treating physician based on the patient's report. The proportions of patients who were compliant with generic imatinib therapy were above 90% when assessed between each of the 7 study visits (mean treatment compliance was 94.5% across the entire 12-month observation period).
All 58 switched patients were in CHR at study enrollment. Fourteen (78%) of 18 patients assessed for cytogenetics were in CCyR, and 41 (87%) of 47 assessed for molecular response were in MMR at the time of switch. According to 2009 ELN guidelines 1 41 (71%) switched patients entered the study with an optimal response; 3 patients had a warning response, 1 patient had a suboptimal response, and 2 patients had a failure response at study enrollment. Eleven patients did not have evaluable measurements at enrollment.
Efficacy
Efficacy data were available for 23 of the 33 first-line patients at 12 months (22 had PCR and 1 had FISH data in the absence of PCR). The other 10 first-line patients had either discontinued therapy (n ¼ 5) or did not have evaluable measurements (n ¼ 5). Twenty-eight (85%) of 33 patients achieved CHR during the first 3 months of treatment with generic imatinib, and all 33 first-line patients achieved CHR after 6 months of treatment. Of the 33 first-line patients, only 4 (12%) were tested for FISH at 12 months; 3 of 4 patients had negative FISH. The 12-month CCyR rates in the intention-to-treat (ITT) population and evaluable patients were 9% and 13%, respectively. Twenty-two (67%) patients were tested for PCR at 12 months; 15 (68%) of 22 patients had MMR. The 12-month MMR rates in the ITT population and evaluable patients were 45% and 65%, respectively.
Twenty first-line patients (61% [95% CI, 51%-86%] of the 33 patients of the ITT population and 87% [95% CI, 73%-100%]) of the 23 evaluable patients achieved an optimal response at 12 months ( Figure 2 ). Three first-line patients who completed the 12-month observation period either experienced a suboptimal response (partial cytogenetic response; n ¼ 1), warning response (less than MMR; n ¼ 1), or treatment failure (less than partial cytogenetic response; n ¼ 1).
Efficacy data were available for 55 of the 58 switched patients at 12 months (54 had PCR and 1 had FISH data in the absence of PCR). Of the 58 switched patients, only 8 (14%) were tested for FISH at 12 months; all 8 patients had negative FISH. The 12-month CCyR rates in the ITT population and evaluable patients were 14% and 14.5%, respectively. Fifty four (93%) patients were tested for PCR at 12 months; 51 (94%) patients had MMR. The 12-month MMR rates in the ITT population and evaluable patients were 88% and 93%, respectively. Fifty-three switched patients (91% [95% CI, 83%-98%] of the ITT population and 96% [95% CI, 91%-100%] of the 55 evaluable patients) had an optimal response at 12 months (Figure 3 ). No switched patients had a suboptimal response or failure.
A post-hoc analysis showed that all patients with an optimal response at 12 months based on the 2009 ELN criteria also achieved an optimal response according to the 2016 NCCN recommendations, whereas 45% of first-line patients in the ITT population achieved an optimal response at 12 months based on the 2013 ELN definitions, and 91% of switched patients in the ITT population achieved optimal response with either the 2009 or 2013 ELN definitions.
With a median follow-up of 12 months, for the total of 91 patients, and assuming all lost to follow-up patients (n ¼ 7) had disease progression at the middle of the follow-up period (ie, month 6), the 12-month progression-free survival and OS rates in the ITT population were 92% and 100%, respectively. 
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Safety
Of the 91 patients in the safety population, 63 (69%) reported AEs, including 27 (82%) first-line patients and 36 (62%) switched patients. A total of 170 AEs were reported (89 in first-line patients and 81 in switched patients). The majority of AEs were mild in both firstline patients (79%) and in switched patients (91%) ( Table 2 ). In both patient groups, most moderate and severe AEs were hematologic, including study drug-related anemia, thrombocytopenia, and neutropenia. Of the 17 severe AEs reported, the following 11 were considered to be related to generic imatinib: anemia (n ¼ 5), arthralgia (n ¼ 2), neutropenia (n ¼ 1), thrombocytopenia (n ¼ 1), idiopathic thrombocytopenia (n ¼ 1), and febrile neutropenia (n ¼ 1). The frequencies of studyedrug-related AEs were similar or lower than those in the Summary of Product Characteristics (SPC) for patented imatinib (Table 3) .
When analyzed in an exploratory manner, higher frequencies of studyedrug-related AEs were found in switched patients than in first-line patients (78% and 46%, respectively), mainly owing to the following AEs: muscle spasms (22% of drug-related AEs in switched patients vs. 5% in first-line patients); vomiting (8% vs. 2%); edema (5% vs. no first-line patients); and fatigue (3% vs. no first-line patients). In contrast, higher frequencies of drug-related neutropenia and thrombocytopenia were found in first-line patients versus switched patients (10% vs. 2% for both AEs). Leukopenia accounted for a similar proportion of drug-related AEs in the firstline patients (2%) and switched patients (3%).
Three serious AEs were reported, all in first-line patients: severe febrile neutropenia (study drug-related) and cholelithiasis and cholecystectomy (not study drug-related). Three other significant AEs were also reported (all studyedrug-related): the first-line patient who had febrile neutropenia also had hyperkalemia, which was likely caused by the former AE, 1 switched patient had systemic lupus erythematosus, and another switched patient had idiopathic thrombocytopenia. Five patients (all first-line patients) permanently discontinued therapy. One patient discontinued owing to an AE (febrile neutropenia). The 4 other patients permanently discontinued because of undisclosed reasons (patient decision).
Discussion
This observational study suggests that the therapeutic effect and safety profile of generic imatinib are comparable with those of patented imatinib in patients with CML in CP when treated in routine clinical practice in Jordan. These favorable outcomes were expected, as generic imatinib is bioequivalent to patented imatinib. 12 In the first-line patients, all patients achieved CHR by 6 months, and 45% of patients achieved MMR by 12 months. By ELN criteria, 61% of the ITT and 87% of the evaluable patients achieved an optimal response by 12 months. In the switched patient cohort, 91% of the ITT and 96% of the evaluable patients maintained or reached an optimal response after switching from patented to generic imatinib. These results, in this real-life observational study, compare favorably with the results from the randomized IRIS trial, in which 69% of patients achieved CCyR, 39% achieved MMR, and 96% achieved CHR at 12 months. 15, 16 Furthermore, in the current study, the overall frequency of reported studyedrug-related AEs was similar to the frequency occurring with patented imatinib in the SPC. 14 The majority of reported AEs were of mild intensity, and only 1 AE (febrile neutropenia) led to drug discontinuation; 94.5% of enrolled patients completed the study. One patient had an AE of systemic lupus erythematosus, which is very rarely associated with CML 17 and is not reported in the imatinib SPC. 14 In addition to the current study, other researchers also report that generic imatinib preparations possess a high level of therapeutic efficacy, at substantially lower costs than patented medications, 9, [18] [19] [20] [21] [22] [23] compatible with some experts' calls for more cost-effective treatment options. 3 For the United States market, Padula et al 9 recently
estimated that first-line treatment with generic imatinib would be on average $91,163 less expensive per patient over 5 years than the "current standard of care" (ie, initiating treatment with a physician's choice of dasatinib, nilotinib, or imatinib). The authors also argued that adoption of generic imatinib would be possible without a clinically meaningful difference in quality-adjusted life-years. Similarly, in a 2014 study conducted in Turkey, 36 patients who received patented imatinib were compared with 26 patients who received generic imatinib. The generic version appeared noninferior to the original molecule regarding efficacy and tolerability and resulted in significant cost savings. 18 A cross-sectional study con- that, in 33 patients with CML initially treated with Imatib (imatinib, Cipla Limited, India), 47% of patients achieved a complete molecular response during an 8-month period. Although the results of these studies with generic imatinib are comparable with the IRIS study, 15 definitive conclusions are limited by the small numbers of patients.
As the current real-life study was noninterventional and observational, the data reflect the medical practices and management of CML in Jordan. This study indicates that FISH is not routinely performed at 12 months in Jordan, which was a major determinant of the low rate of CCyR observed in this study. As expected, slight differences occurred in clinical practice, such as differences in the choice of laboratory tests (PCR, FISH, and complete blood count) AE frequencies are: very common > 10%, common 1% to 10%, uncommon 0.1% to < 1%, rare 0.01% to < 0.1%, very rare < 0.01%. Abbreviations: AE ¼ adverse event; E ¼ number of adverse events; SAE ¼ serious adverse event; SPC ¼ summary of product characteristics.
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In particular, all patients in this study with an optimal response at 12 months based on the 2009 ELN criteria also achieved an optimal response according to the 2016 NCCN recommendations, whereas 61% versus 45% of first-line patients in the ITT population achieved an optimal response at 12 months based on the 2009 and 2013 ELN definitions, respectively, and 91% of switched patients in the ITT population achieved optimal response with either the 2009 or 2013 ELN definitions. Notably, the 16% difference in optimal response in the first-line patients was because of reclassification of patients from optimal response to warning response. Higher frequencies of studyedrug-related AEs were found in switched patients than in first-line patients (78% and 46%, respectively). The difference could be explained by a longer disease duration and longer exposure to imatinib in switched patients.
The results of this observational study suggest that generic imatinib in a Middle Eastern population in routine clinical practice is comparable to patented imatinib, and to that of the global population. Use of generic imatinib is likely to reduce healthcare expenditure per patient and increase patient access to this muchneeded medication.
Clinical Practice Points
The outcome of patients with CML has been revolutionized by imatinib. The 2009 and 2013 ELN guidelines advise the use of imatinib 400 mg daily as first-line therapy for patients with CML in CP. The high economic burden of patented medications such as imatinib has been of concern, and generic imatinib therapy is being globally considered owing to cost considerations. Although second-generation TKIs (eg, dasatinib or nilotinib) produce more rapid molecular responses than imatinib, 5-year OS is similar to that of imatinib. Thus, generic imatinib is more cost-effective than other TKIs, leading to consensus recommendations that most patients should receive imatinib as first-line therapy. This real-life, multicenter, prospective, observational study suggests that the therapeutic effect and safety profile of generic imatinib are comparable with those of patented imatinib in patients with CML in CP when treated with first-line generic imatinib or when switched from patented to generic imatinib in routine clinical practice. Use of generic imatinib is likely to reduce health care expenditure per patient and increase patient access to this much-needed medication.
